[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "(858) 267-4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 48, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 917304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 49, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 48, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 630312, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher P. Horan", "age": 56, "title": "Chief Technical Operations Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 612234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Neha  Krishnamohan", "age": 36, "title": "CFO & Executive VP of Corporate Development", "yearBorn": 1987, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thorsten  Graef M.D., Ph.D.", "age": 47, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Heather  Raymon Ph.D.", "age": 59, "title": "Senior Vice President of Research & Early Development", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eugene  Helsel", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. K. C Lim Pharm.D.", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.38, "open": 11.56, "dayLow": 11.27, "dayHigh": 12.07, "regularMarketPreviousClose": 11.38, "regularMarketOpen": 11.56, "regularMarketDayLow": 11.27, "regularMarketDayHigh": 12.07, "forwardPE": -3.879479, "volume": 66451, "regularMarketVolume": 66451, "averageVolume": 128848, "averageVolume10days": 66080, "averageDailyVolume10Day": 66080, "bid": 11.86, "ask": 11.97, "bidSize": 500, "askSize": 100, "marketCap": 289259360, "fiftyTwoWeekLow": 9.71, "fiftyTwoWeekHigh": 16.0, "priceToSalesTrailing12Months": 9.88718, "fiftyDayAverage": 11.242121, "twoHundredDayAverage": 11.242121, "currency": "USD", "enterpriseValue": 194853568, "profitMargins": -1.11174, "floatShares": 18698, "sharesOutstanding": 24287100, "sharesShort": 28175, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0023, "heldPercentInsiders": 0.20007, "heldPercentInstitutions": 0.65376, "shortRatio": 0.35, "shortPercentOfFloat": 0.0023999999, "impliedSharesOutstanding": 24287100, "bookValue": -235.57, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -32525000, "trailingEps": -0.93, "forwardEps": -3.07, "enterpriseToRevenue": 6.66, "enterpriseToEbitda": -6.605, "52WeekChange": -0.051666677, "SandP52WeekChange": 0.24014747, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ARTV", "underlyingSymbol": "ARTV", "shortName": "Artiva Biotherapeutics, Inc.", "longName": "Artiva Biotherapeutics, Inc.", "firstTradeDateEpochUtc": 1721395800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8e252093-be09-3198-b7f1-62334b202526", "messageBoardId": "finmb_672643147", "gmtOffSetMilliseconds": -14400000, "currentPrice": 11.91, "targetHighPrice": 23.0, "targetLowPrice": 18.0, "targetMeanPrice": 21.25, "targetMedianPrice": 22.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 46556000, "totalCashPerShare": 57.391, "ebitda": -29501000, "totalDebt": 15765000, "quickRatio": 4.435, "currentRatio": 4.595, "totalRevenue": 29256000, "debtToEquity": 62.273, "revenuePerShare": 36.149, "operatingCashflow": -50194000, "grossMargins": 1.0, "ebitdaMargins": -1.0083699, "operatingMargins": -1.08836, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]